department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ilaris · pharmadog

pharmadog
drugs
Ilaris

drug

patient view →

canakinumab

Marketedupdated 2mo ago

by $NVS NOVARTIS AG

Approved

community read0 votes

all catalysts(1)

phase 2 completion · 1

phase 2 completion

Ohio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

brand

Ilaris

generic

canakinumab

indication

Familial Mediterranean Fever

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagOncology3 co-mentions · 1 sources
companyOhio State University Comprehensive Cancer Center1 co-mentions · 1 sources
tagPulmonology1 co-mentions · 1 sources
tagNSCLC1 co-mentions · 1 sources

Trials studying canakinumab

EP1A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinomacompletedn=17
phase2A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemiarecruitingn=76
phase3Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDcompletedn=14
phase3Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjectsterminatedn=673
—Ilaris NIS in Korearecruitingn=25
phase2Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAactive not recruitingn=13
phase2A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)terminatedn=23
phase2Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Diseaseterminatedn=34

more trials →